The revised Regulations on the Supervision and Administration of Medical Devices (State Council Decree No. 739), in force since June 1, 2021, are the cornerstone of China's device regulatory framework. They establish the registrant system, risk-based classification and full-lifecycle oversight — and define the logic of market access for overseas products. Below are the five points that matter most to overseas manufacturers.
1. The registrant system: accountability concentrates on the holder
The most consequential change is the full implementation of the medical device registrant/record-holder system. Whoever holds the registration or filing is responsible for the product's entire lifecycle — from development and manufacturing to distribution, post-market surveillance and recalls. Accountability no longer splits across manufacturers or distributors.
For overseas manufacturers, this means you, as the foreign holder of a Chinese registration, must genuinely own these obligations and implement them in China through lawful arrangements. Understanding this boundary of responsibility is lesson one of entering the market.
2. The China legal agent: a statutory role
Overseas registrants and record-holders must designate a Chinese enterprise legal person as their agent, to handle registration and filing, adverse event monitoring, product recalls and related matters. The agent is a regulatory role — fundamentally different from a commercial distributor: distribution solves selling, the agent answers to the regulator. The two cannot replace each other, and the agency arrangement is part of the submission dossier.
Typical agent responsibilities include:
- Communicating with the authorities on the holder's behalf for registration, filing and changes
- Supporting adverse event monitoring and reporting within required timelines
- Cooperating in product recalls and related regulatory measures
- Keeping the holder informed of regulatory changes in China
3. Classification and submission pathways
China manages devices in three risk classes; the class determines the pathway, the reviewing authority and the timeline expectation. Domestic products are received by different authorities depending on class, while registration and filing of foreign products are submitted uniformly to the National Medical Products Administration (NMPA).
| Class | Pathway | Domestic products | Foreign products |
|---|---|---|---|
| Class I | Filing | Municipal-level authority | NMPA |
| Class II | Registration | Provincial medical products authority | NMPA |
| Class III | Registration | NMPA | NMPA |
Classification follows the Medical Device Classification Catalogue and classification determination documents. A wrong class determination means the wrong pathway and a dossier built in vain — confirm it before any paperwork begins.
4. More flexible clinical evaluation pathways
Not every product needs a clinical trial. The framework provides risk-based pathways:
- Exemption — products listed in the exemption catalogue may be supported by non-clinical evidence;
- Predicate-based evaluation — safety and performance argued by comparison with marketed equivalents;
- Clinical trials — where truly needed, eligible products may leverage foreign clinical data under the rules, avoiding duplication.
For manufacturers with EU, US or other market experience, planning the clinical pathway early typically shortens timelines and reduces cost significantly.
5. Full-lifecycle duties and tougher penalties
Registration is a starting line, not a finish. Lifecycle oversight implies continuing obligations: maintaining the quality management system, adverse event monitoring and re-evaluation, recalls where necessary, and renewal and change management of registrations. Penalties have increased sharply, with fines raised and liability reaching responsible individuals.
- Adverse event monitoring and reporting
- Registration validity management — renewal must be requested six months before expiry
- Change management — substantive changes and record changes follow different routes
- Continued conformity of product technical requirements
